Editorial Analysis – TAK Stock Update

By Harris Dyer • Wednesday, May 27 16:11 • Permanent Link

Large-cap Health Care company Takeda Pharmaceutical has moved 1.8% so far today on a volume of 3,024,219, compared to its average of 2,989,150. In contrast, the S&P 500 index moved -0.0%.

Takeda Pharmaceutical trades -20.77% away from its average analyst target price of $20.4 per share. The 3 analysts following the stock have set target prices ranging from $18.64628 to $21.77311, and on average have given Takeda Pharmaceutical a rating of buy.

If you are considering an investment in TAK, you'll want to know the following:

Takeda Pharmaceutical's current price is -99.4% below its Graham number of $2486.38, which implies the stock has a margin of safety
Takeda Pharmaceutical has moved 8.8% over the last year, and the S&P 500 logged a change of 27.7%
Based on its trailing earnings per share of 0.38, Takeda Pharmaceutical has a trailing 12 month Price to Earnings (P/E) ratio of 42.5 while the S&P 500 average is 29.3
TAK has a forward P/E ratio of 30.5 based on its forward 12 month price to earnings (EPS) of $0.53 per share
The company has a price to earnings growth (PEG) ratio of 0.4 — a number near or below 1 signifying that Takeda Pharmaceutical is fairly valued compared to its estimated growth potential
Its Price to Book (P/B) ratio is 1.07 compared to its sector average of 3.19
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.